Related Experiment Video
Updated: Mar 16, 2026
Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention
Published on: September 18, 2015
Patiromer: The First Potassium Binder Approved in Over 50 Years
Betty N Vu1, Alyssa Mae De Castro, David Shottland
1From the *Department of Pharmacy Practice, Midwestern University Chicago College of Pharmacy/RUSH University Medical Center, Downers Grove, IL; †Department of Pharmacy, Montefiore Medical Center, Bronx, NY; ‡Department of Medicine, Boston University Medical Center, Boston, MA; and §Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, NY.
Insights
Patiromer effectively lowers potassium levels in patients with chronic kidney disease and other conditions, enabling safer use of vital RAAS inhibitor medications. This treatment offers a new option for managing hyperkalemia and its associated risks.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Limited management options for hyperkalemia exist, particularly for patients with chronic kidney disease (CKD), diabetic nephropathy, hypertension, and heart failure on renin-angiotensin-aldosterone system (RAAS) inhibitors.
- Hyperkalemia poses a life-threatening risk, complicating the use of RAAS inhibitors, which offer significant mortality benefits and organ protection, especially in CKD and heart failure.
Purpose of the Study:
- To evaluate the efficacy and tolerability of patiromer, a novel potassium-binding polymer, for managing hyperkalemia in patients with CKD, diabetic nephropathy, and heart failure receiving RAAS inhibitor therapy.
Main Methods:
- Patiromer, a nonabsorbed cation-exchange polymer, binds potassium in the gastrointestinal tract, exchanging it for calcium.
- Clinical studies (PEARL-HF, AMETHYST-DN, OPAL-HK) assessed patiromer's potassium-lowering effects in patients with heart failure, diabetic nephropathy, and CKD on RAAS inhibitors.
Main Results:
- Patiromer demonstrated significant potassium-lowering effects in both normokalemic and hyperkalemic patients across the studied conditions.
- The treatment was generally effective and well-tolerated, with most adverse events being gastrointestinal in nature.
Conclusions:
- Patiromer shows promise for the chronic management of hyperkalemia, facilitating optimized RAAS inhibitor therapy.
- This can lead to delayed CKD progression and improved mortality outcomes in heart failure patients.
- Further research is warranted for long-term use, larger populations, and drug-drug interactions.
Abstract:
For over 50 years, there have been limited options for the management of hyperkalemia, especially among patients with chronic kidney disease (CKD), diabetic nephropathy, hypertension, and heart failure, who were receiving concomitant renin-angiotensin-aldosterone system (RAAS) inhibitor therapy. Hyperkalemia is a potential, life-threatening electrolyte abnormality that frequently challenges clinicians from maximizing the mortality benefit and organ-protective properties of RAAS inhibitors especially in CKD and heart failure populations. Patiromer is a novel nonabsorbed, cation-exchange polymer that binds and exchanges potassium for calcium, predominantly in the gastrointestinal tract. It has demonstrated potassium-lowering effects in normo- or hyperkalemic patients on concomitant RAAS inhibitors with heart failure, diabetic nephropathy, and CKD, in the PEARL-HF, AMETHYST-DN, and OPAL-HK studies, respectively. Across all studies, it appears to be generally effective and well tolerated, with adverse events predominantly gastrointestinal in nature. Additional investigational studies are needed to explore its use for an extended duration of treatment and in larger patient populations, as well as exploring drug-drug interactions. Overall, patiromer demonstrates a promising role in the chronic management of hyperkalemia that will allow optimization of RAAS inhibitor therapy, thus delaying progression of CKD and improving the mortality benefit in heart failure patients.
Related Concept Videos
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:25Antihypertensive Drugs: Direct Renin Inhibitors
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...